Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 281

1.

Ciliated muconodular papillary tumor of the lung: a case report and literature review.

Abe M, Osoegawa A, Miyawaki M, Noda D, Karashima T, Takumi Y, Hashimoto T, Okamoto T, Daa T, Sugio K.

Gen Thorac Cardiovasc Surg. 2019 Nov 20. doi: 10.1007/s11748-019-01252-x. [Epub ahead of print]

PMID:
31749068
2.

Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401.

Iwama E, Goto Y, Murakami H, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Nishitsuji M, Akamatsu H, Morinaga R, Akagi T, Shimose T, Tokunaga S, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I.

Oncologist. 2019 Oct 30. pii: theoncologist.2019-0728. doi: 10.1634/theoncologist.2019-0728. [Epub ahead of print]

3.

Erlotinib and bevacizumab combination therapy for afatinib-refractory leptomeningeal carcinomatosis from EGFR-mutated lung cancer.

Abe M, Osoegawa A, Karashima T, Takumi Y, Kobayashi R, Hashimoto T, Miyawaki M, Takeuchi H, Okamoto T, Sugio K.

Int Cancer Conf J. 2019 Jan 18;8(2):81-85. doi: 10.1007/s13691-019-00358-6. eCollection 2019 Apr.

4.

Randomized phase II study of pemetrexed or pemetrexed plus bevacizumab for elderly patients with previously untreated non-squamous non-small cell lung cancer: Results of the Lung Oncology Group in Kyushu (LOGIK1201).

Fukuda M, Kitazaki T, Ogawara D, Ichiki M, Mukae H, Maruyama R, Nakagaki N, Shimada M, Ikeda T, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Okamoto I, Ichinose Y, Sugio K.

Lung Cancer. 2019 Jun;132:1-8. doi: 10.1016/j.lungcan.2019.01.008. Epub 2019 Apr 5.

PMID:
31097081
5.

Elevated red cell distribution width to platelet count ratio predicts poor prognosis in patients with breast cancer.

Takeuchi H, Abe M, Takumi Y, Hashimoto T, Miyawaki M, Okamoto T, Sugio K.

Sci Rep. 2019 Feb 28;9(1):3033. doi: 10.1038/s41598-019-40024-8.

6.

Transport of 2,4-dichloro phenoxyacetic acid by human Na+-coupled monocarboxylate transporter 1 (hSMCT1, SLC5A8).

Sugio K, Inoda D, Masuda M, Azumaya I, Sasaki S, Shimono K, Ganapathy V, Miyauchi S.

Drug Metab Pharmacokinet. 2019 Feb;34(1):95-103. doi: 10.1016/j.dmpk.2018.10.004. Epub 2018 Nov 8.

PMID:
30583944
7.

A phase II randomized trial of adjuvant chemotherapy with S-1 versus S-1 plus cisplatin for completely resected pathological stage II/IIIA non-small cell lung cancer.

Okamoto T, Yano T, Shimokawa M, Takeo S, Yamazaki K, Sugio K, Takenoyama M, Nagashima A, Tsukamoto S, Hamatake M, Yokoyama H, Ueda H, Motohiro A, Tagawa T, Shoji F, Kometani T, Saito G, Fukuyama Y, Toyokawa G, Osoegawa A, Emi Y, Maehara Y; Kyushu University Lung Surgery Study Group (KLSS) Japan.

Lung Cancer. 2018 Oct;124:255-259. doi: 10.1016/j.lungcan.2018.08.015. Epub 2018 Aug 19.

PMID:
30268470
8.

Intratumoral heterogeneity of copy number variation in lung cancer harboring L858R via immunohistochemical heterogeneous staining.

Hashimoto T, Osoegawa A, Takumi Y, Abe M, Kobayashi R, Miyawaki M, Takeuchi H, Okamoto T, Sugio K.

Lung Cancer. 2018 Oct;124:241-247. doi: 10.1016/j.lungcan.2018.08.013. Epub 2018 Aug 13.

PMID:
30268468
9.

[Expectation for Surgery in Multi-modality Treatment in Non-small Cell Lung Cancer].

Sugio K.

Kyobu Geka. 2018 Apr;71(4):249-255. Japanese.

PMID:
29755097
10.

Acquired resistance to an epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) in an uncommon G719S EGFR mutation.

Osoegawa A, Hashimoto T, Takumi Y, Abe M, Yamada T, Kobayashi R, Miyawaki M, Takeuchi H, Okamoto T, Sugio K.

Invest New Drugs. 2018 Dec;36(6):999-1005. doi: 10.1007/s10637-018-0592-y. Epub 2018 Mar 28.

PMID:
29594878
11.

Clinicopathological features of younger (aged ≤ 50 years) lung adenocarcinoma patients harboring the EML4-ALK fusion gene.

Kometani T, Sugio K, Osoegawa A, Seto T, Ichinose Y.

Thorac Cancer. 2018 May;9(5):563-570. doi: 10.1111/1759-7714.12616. Epub 2018 Mar 8.

12.

Clinical and Genetic Implications of Mutation Burden in Squamous Cell Carcinoma of the Lung.

Okamoto T, Takada K, Sato S, Toyokawa G, Tagawa T, Shoji F, Nakanishi R, Oki E, Koike T, Nagahashi M, Ichikawa H, Shimada Y, Watanabe S, Kikuchi T, Akazawa K, Lyle S, Takabe K, Okuda S, Sugio K, Wakai T, Tsuchida M, Maehara Y.

Ann Surg Oncol. 2018 Jun;25(6):1564-1571. doi: 10.1245/s10434-018-6401-1. Epub 2018 Mar 2.

PMID:
29500766
13.

Cancer-associated retinopathy after surgery for breast cancer: a case report and review of the literature.

Kamei M, Fujitomi Y, Kondo Y, Adachi T, Shibata K, Takumi Y, Abe M, Sugio K.

Surg Case Rep. 2018 Jan 23;4(1):10. doi: 10.1186/s40792-018-0418-3.

14.

The Positive Relationship Between γH2AX and PD-L1 Expression in Lung Squamous Cell Carcinoma.

Osoegawa A, Hiraishi H, Hashimoto T, Takumi Y, Abe M, Takeuchi H, Miyawaki M, Okamoto T, Sugio K.

In Vivo. 2018 Jan-Feb;32(1):171-177.

15.

A proposal for a comprehensive risk scoring system for predicting postoperative complications in octogenarian patients with medically operable lung cancer: JACS1303.

Saji H, Ueno T, Nakamura H, Okumura N, Tsuchida M, Sonobe M, Miyazaki T, Aokage K, Nakao M, Haruki T, Ito H, Kataoka K, Okabe K, Tomizawa K, Yoshimoto K, Horio H, Sugio K, Ode Y, Takao M, Okada M, Chida M; Committee for Scientific Affairs, The Japanese Association for Chest Surgery, Tokyo, Japan.

Eur J Cardiothorac Surg. 2018 Apr 1;53(4):835-841. doi: 10.1093/ejcts/ezx415.

PMID:
29240884
16.

The prognostic impact of the platelet distribution width-to-platelet count ratio in patients with breast cancer.

Takeuchi H, Abe M, Takumi Y, Hashimoto T, Kobayashi R, Osoegawa A, Miyawaki M, Okamoto T, Sugio K.

PLoS One. 2017 Dec 7;12(12):e0189166. doi: 10.1371/journal.pone.0189166. eCollection 2017.

17.

Chemical Modulation of the Human Oligopeptide Transporter 1, hPepT1.

Colas C, Masuda M, Sugio K, Miyauchi S, Hu Y, Smith DE, Schlessinger A.

Mol Pharm. 2017 Dec 4;14(12):4685-4693. doi: 10.1021/acs.molpharmaceut.7b00775. Epub 2017 Nov 15.

18.

Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu 1401).

Iwama E, Goto Y, Murakami H, Harada T, Tsumura S, Sakashita H, Mori Y, Nakagaki N, Fujita Y, Seike M, Bessho A, Ono M, Okazaki A, Akamatsu H, Morinaga R, Ushijima S, Shimose T, Tokunaga S, Hamada A, Yamamoto N, Nakanishi Y, Sugio K, Okamoto I.

J Thorac Oncol. 2017 Jul;12(7):1161-1166. doi: 10.1016/j.jtho.2017.02.012. Epub 2017 Feb 24.

19.

Phase I study of irinotecan for previously treated lung cancer patients with the UGT1A1*28 or *6 polymorphism: Results of the Lung Oncology Group in Kyushu (LOGIK1004A).

Fukuda M, Shimada M, Kitazaki T, Nagashima S, Hashiguchi K, Ebi N, Takayama K, Nakanishi Y, Semba H, Harada T, Seto T, Okamoto I, Ichinose Y, Sugio K.

Thorac Cancer. 2017 Jan;8(1):40-45. doi: 10.1111/1759-7714.12407. Epub 2016 Nov 24.

20.

The Prognostic Impact of Jumonji Domain-containing 2B in Patients with Resected Lung Adenocarcinoma.

Toyokawa G, Taguchi K, Edagawa M, Shimamatsu S, Toyozawa R, Nosaki K, Hirai F, Yamaguchi M, Shimokawa M, Seto T, Takenoyama M, Hamamoto R, Sugio K, Ichinose Y.

Anticancer Res. 2016 Sep;36(9):4841-6.

PMID:
27630338
21.

Prospective study of the UGT1A1*27 gene polymorphism during irinotecan therapy in patients with lung cancer: Results of Lung Oncology Group in Kyusyu (LOGIK1004B).

Fukuda M, Suetsugu T, Shimada M, Kitazaki T, Hashiguchi K, Kishimoto J, Harada T, Seto T, Ebi N, Takayama K, Sugio K, Semba H, Nakanishi Y, Ichinose Y.

Thorac Cancer. 2016 Jul;7(4):467-72. doi: 10.1111/1759-7714.12360. Epub 2016 May 11.

22.

Phase II Trial of Erlotinib in Elderly Patients with Previously Treated Non-small Cell Lung Cancer: Results of the Lung Oncology Group in Kyushu (LOGiK-0802).

Yamada K, Azuma K, Takeshita M, Uchino J, Nishida C, Suetsugu T, Kondo A, Harada T, Eida H, Kishimoto J, Eriguchi G, Takayama K, Nakanishi Y, Sugio K.

Anticancer Res. 2016 Jun;36(6):2881-7.

PMID:
27272800
23.

Spontaneous splenic rupture accompanied by hepatic arterial dissection in a patient with autoimmune haemorrhaphilia due to anti-factor XIII antibodies.

Tsuda M, Kiyasu J, Sugio K, Hidaka D, Ikeda M, Fujioka E, Souri M, Osaki T, Yufu Y, Ichinose A.

Haemophilia. 2016 Jul;22(4):e314-7. doi: 10.1111/hae.12940. Epub 2016 May 11. No abstract available.

PMID:
27167212
24.

Pemetrexed-induced scleroderma-like conditions in the lower legs of a patient with non-small cell lung carcinoma.

Ishikawa K, Sakai T, Saito-Shono T, Miyawaki M, Osoegawa A, Sugio K, Ono A, Mori H, Nishida H, Yokoyama S, Okamoto O, Fujiwara S, Hatano Y.

J Dermatol. 2016 Sep;43(9):1071-4. doi: 10.1111/1346-8138.13354. Epub 2016 Mar 15.

PMID:
26992088
25.

A case of breast cancer involving a ventriculoperitoneal shunt.

Kamei M, Kikuchi N, Ichimura H, Chujo M, Takahashi Y, Sugio K.

Surg Case Rep. 2016 Dec;2(1):8. doi: 10.1186/s40792-016-0136-7. Epub 2016 Feb 6.

26.

The clinical manifestations and treatment of male breast cancer: a report of three cases.

Suehiro S, Abe M, Takumi Y, Hashimoto T, Kamei M, Osoegawa A, Miyawaki M, Sugio K.

Surg Case Rep. 2015 Dec;1(1):92. doi: 10.1186/s40792-015-0103-8. Epub 2015 Oct 5.

27.

Mutations of the EGFR, K-ras, EML4-ALK, and BRAF genes in resected pathological stage I lung adenocarcinoma.

Ohba T, Toyokawa G, Osoegawa A, Hirai F, Yamaguchi M, Taguchi K, Seto T, Takenoyama M, Ichinose Y, Sugio K.

Surg Today. 2016 Sep;46(9):1091-8. doi: 10.1007/s00595-015-1295-z. Epub 2015 Dec 28.

PMID:
26711128
28.

Sodium-glucose cotransporter 2 inhibitor luseogliflozin improves glycaemic control, assessed by continuous glucose monitoring, even on a low-carbohydrate diet.

Nishimura R, Omiya H, Sugio K, Ubukata M, Sakai S, Samukawa Y.

Diabetes Obes Metab. 2016 Jul;18(7):702-6. doi: 10.1111/dom.12611. Epub 2016 Jan 15.

29.

Adenomyoepithelioma of the breast coexisting with ductal carcinoma in situ: a case report and review of the literature.

Kamei M, Daa T, Miyawaki M, Suehiro S, Sugio K.

Surg Case Rep. 2015 Sep 11;1:81. doi: 10.1186/s40792-015-0083-8. eCollection 2015 Dec.

30.

Prognostic Factors for Survival after Resection of Pulmonary Metastases from Colorectal Carcinoma.

Osoegawa A, Kometani T, Fukuyama S, Hirai F, Seto T, Sugio K, Ichinose Y.

Ann Thorac Cardiovasc Surg. 2016;22(1):6-11. doi: 10.5761/atcs.oa.14-00345. Epub 2015 Aug 19.

31.

Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study.

Nishimura R, Osonoi T, Kanada S, Jinnouchi H, Sugio K, Omiya H, Ubukata M, Sakai S, Samukawa Y.

Diabetes Obes Metab. 2015 Aug;17(8):800-4. doi: 10.1111/dom.12481. Epub 2015 Jun 4.

32.

Current status of induction treatment for N2-Stage III non-small cell lung cancer.

Yamaguchi M, Sugio K.

Gen Thorac Cardiovasc Surg. 2014 Nov;62(11):651-9. doi: 10.1007/s11748-014-0447-1. Epub 2014 Jul 18. Review.

PMID:
25355643
33.

A simple risk scoring system for predicting acute exacerbation of interstitial pneumonia after pulmonary resection in lung cancer patients.

Sato T, Kondo H, Watanabe A, Nakajima J, Niwa H, Horio H, Okami J, Okumura N, Sugio K, Teramukai S, Kishi K, Ebina M, Sugiyama Y, Kondo T, Date H.

Gen Thorac Cardiovasc Surg. 2015 Mar;63(3):164-72. doi: 10.1007/s11748-014-0487-6. Epub 2014 Oct 30.

PMID:
25352311
34.

Non-small cell lung cancer patients with EML4-ALK fusion gene are insensitive to cytotoxic chemotherapy.

Morodomi Y, Takenoyama M, Inamasu E, Toyozawa R, Kojo M, Toyokawa G, Shiraishi Y, Takenaka T, Hirai F, Yamaguchi M, Taguchi K, Seto T, Sugio K, Ichinose Y.

Anticancer Res. 2014 Jul;34(7):3825-30.

PMID:
24982409
35.

Phase II study of zoledronic acid combined with docetaxel for non-small-cell lung cancer: West Japan Oncology Group.

Murakami H, Yamanaka T, Seto T, Sugio K, Okamoto I, Sawa T, Hirashima T, Takeda K, Atagi S, Fukuoka M, Nakanishi Y, Nakagawa K, Yamamoto N.

Cancer Sci. 2014 Aug;105(8):989-95. doi: 10.1111/cas.12448. Epub 2014 Jul 12.

36.

Preoperative concurrent chemoradiotherapy of S-1/cisplatin for stage III non-small cell lung cancer.

Yamaguchi M, Toyokawa G, Ohba T, Sasaki T, Kometani T, Hamatake M, Hirai F, Taguchi K, Yamanaka T, Seto T, Takenoyama M, Sugio K, Ichinose Y.

Ann Thorac Surg. 2013 Nov;96(5):1783-9. doi: 10.1016/j.athoracsur.2013.06.036. Epub 2013 Aug 30.

PMID:
23998404
37.

Mutations of the EGFR and K-ras genes in resected stage I lung adenocarcinoma and their clinical significance.

Ohba T, Toyokawa G, Kometani T, Nosaki K, Hirai F, Yamaguchi M, Hamatake M, Seto T, Ichinose Y, Sugio K.

Surg Today. 2014 Mar;44(3):478-86. doi: 10.1007/s00595-013-0589-2. Epub 2013 Apr 23.

PMID:
23609009
38.

The effect of CYP2C19 polymorphism on the safety, tolerability, and pharmacokinetics of tivantinib (ARQ 197): results from a phase I trial in advanced solid tumors.

Yamamoto N, Murakami H, Nishina T, Hirashima T, Sugio K, Muro K, Takahashi T, Naito T, Yasui H, Akinaga S, Koh Y, Boku N.

Ann Oncol. 2013 Jun;24(6):1653-9. doi: 10.1093/annonc/mdt014. Epub 2013 Feb 14.

PMID:
23413279
39.

A rare point mutation in the Ras oncogene in hepatocellular carcinoma.

Taketomi A, Shirabe K, Muto J, Yoshiya S, Motomura T, Mano Y, Ikegami T, Yoshizumi T, Sugio K, Maehara Y.

Surg Today. 2013 Mar;43(3):289-92. doi: 10.1007/s00595-012-0462-8. Epub 2012 Dec 26.

PMID:
23266750
40.

Regression of thymoma associated with a multilocular thymic cyst: report of a case.

Toyokawa G, Taguchi K, Ohba T, Hirai F, Yamaguchi M, Hamatake M, Seto T, Nishiyama K, Shida Y, Sugio K, Ichinose Y.

Surg Today. 2014 Mar;44(3):577-80. doi: 10.1007/s00595-012-0436-x. Epub 2012 Nov 25.

PMID:
23184327
41.

First case of combined small-cell lung cancer with adenocarcinoma harboring EML4-ALK fusion and an exon 19 EGFR mutation in each histological component.

Toyokawa G, Taguchi K, Ohba T, Morodomi Y, Takenaka T, Hirai F, Yamaguchi M, Seto T, Takenoyama M, Sugio K, Ichinose Y.

J Thorac Oncol. 2012 Dec;7(12):e39-e41. doi: 10.1097/JTO.0b013e3182762bcb. No abstract available.

42.

[II. Recurrence and second primary lung cancer in patients after resection of stage I lung cancer].

Sugio K.

Gan To Kagaku Ryoho. 2012 Aug;39(8):1197-200. Review. Japanese. No abstract available.

PMID:
22984696
43.

A case of clear cell adenocarcinoma arising from the urethral diverticulum: Utility of urinary cytology and immunohistochemistry.

Nakatsuka S, Taguchi I, Nagatomo T, Yamane M, Sugio K, Yoshino R, Oku K, Nagano T, Kimura H, Nakajo K, Kawabata G.

Cytojournal. 2012;9:11. doi: 10.4103/1742-6413.95528. Epub 2012 Apr 30.

44.

[Combined resection of the thoracic wall and diaphragm for pulmonary metastasis of malignant fibrous histiocytoma].

Sugio K.

Kyobu Geka. 2011 Dec;64(13):1162. Japanese. No abstract available.

PMID:
22315724
45.

[Interstitial pneumonitis].

Hirai F, Toyokawa G, Ohba T, Kitajima H, Yamaguchi M, Maruyama R, Hamatake M, Seto T, Sugio K, Ichinose Y.

Gan To Kagaku Ryoho. 2011 Nov;38(11):1782-4. Japanese.

PMID:
22083185
46.

Angiomyolipomas of the mediastinum and the lung.

Morita K, Shida Y, Shinozaki K, Uehara S, Seto T, Sugio K, Ichinose Y, Nishiyama K, Matsuo Y, Hatakenaka M, Honda H.

J Thorac Imaging. 2012 Jan;27(1):W21-3. doi: 10.1097/RTI.0b013e31823150c7.

PMID:
22071676
47.

Prognosis and therapeutic response according to the World Health Organization histological classification in advanced thymoma.

Tagawa T, Kometani T, Yamazaki K, Okamoto T, Wataya H, Seto T, Fukuyama S, Osoegawa A, Hirai F, Sugio K, Ichinose Y.

Surg Today. 2011 Dec;41(12):1599-604. doi: 10.1007/s00595-011-4522-2. Epub 2011 Oct 4.

PMID:
21969191
48.

Concurrent chemoradiotherapy using cisplatin plus S-1, an oral fluoropyrimidine, followed by surgery for selected patients with stage III non-small cell lung cancer: a single-center feasibility study.

Maruyama R, Hirai F, Ondo K, Kometani T, Hamatake M, Seto T, Sugio K, Ichinose Y.

Surg Today. 2011 Nov;41(11):1492-7. doi: 10.1007/s00595-011-4509-z. Epub 2011 Oct 4.

PMID:
21969151
49.

LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma.

Osoegawa A, Kometani T, Nosaki K, Ondo K, Hamatake M, Hirai F, Seto T, Sugio K, Ichinose Y.

Jpn J Clin Oncol. 2011 Sep;41(9):1132-7. doi: 10.1093/jjco/hyr102. Epub 2011 Aug 4.

PMID:
21816872
50.

Signet ring cell adenocarcinoma of the lung with an EML4-ALK fusion gene mimicking mucinous (colloid) adenocarcinoma: a case report.

Ohba T, Sugio K, Kometani T, Yamaguchi M, Hamatake M, Nosaki K, Takeoka H, Kitajima H, Hirai F, Seto T, Taguchi K, Nishiyama K, Shida Y, Ichinose Y.

Lung Cancer. 2011 Sep;73(3):375-8. doi: 10.1016/j.lungcan.2011.05.016. Epub 2011 Jun 29.

PMID:
21719143

Supplemental Content

Support Center